- Report
- March 2024
- 128 Pages
Middle East, Africa
From €1432EUR$1,500USD£1,199GBP
- Report
- August 2022
United States
From €1851EUR$1,940USD£1,551GBP
- Report
- August 2022
Global
From €945EUR$990USD£792GBP
- Drug Pipelines
- October 2020
- 170 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Drug Pipelines
- July 2020
- 222 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- March 2024
- 185 Pages
Asia Pacific
€4767EUR$4,995USD£3,994GBP
- Report
- January 2023
- 28 Pages
Global
€11691EUR$12,250USD£9,796GBP
- Report
- October 2022
- 25 Pages
Global
€11691EUR$12,250USD£9,796GBP
- Report
- February 2024
- 99 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2023
- 92 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- July 2022
- 136 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2022
- 52 Pages
Global
From €1909EUR$2,000USD£1,599GBP
The Alopecia Drug market is a subset of the Immune Disorders Drugs market, which focuses on treatments for autoimmune diseases. Alopecia is an autoimmune disorder that causes hair loss, and drugs used to treat it are designed to reduce inflammation and suppress the immune system. These drugs are typically administered orally or topically, and may include corticosteroids, immunosuppressants, and biologics.
The Alopecia Drug market is highly competitive, with many companies developing treatments for the disorder. Some of the major players in the market include Pfizer, Novartis, Merck, Johnson & Johnson, and GlaxoSmithKline. Other companies, such as Sun Pharmaceuticals, Cipla, and Dr. Reddy's Laboratories, are also active in the market. Show Less Read more